# Ventripoint and Lishman Global Sign Non-binding Term Sheet Defining License for VMS+ Technology

**Toronto, Ontario, July 11, 2025** – Ventripoint Diagnostics Ltd. ("**Ventripoint**" or the "**Corporation**", TSXV:VPT) is pleased to announce that it has signed a non-binding term sheet with Lishman Global Inc. outlining the exclusive , non-transferable license of Ventripoint technology for use within Lishman's echocardiography image platform in the People's Republic of China including the Special Administrative Regions of Hong Kong and Macao (the "Territory").

Previously, Lishman's Chinese subsidiary had received CFDA approval and a Certificate of Production (CoP) from the CFDA in the People's Republic of China for the VMS+ product used for analysis of the right ventricle (RV) only of the heart. The subsidiary has a GMP certified manufacturing facility in China that is able to produce at a scale capable of addressing the Chinese market.

Upon execution, the new license will enable Lishman and its subsidiaries to fully integrate VMS+ 4.0 within its cart-based and hybrid echocardiography platforms and to market the technology within the Territory. The final license will specify annual minimum volumes once CFDA approval has been secured. Lishman has placed a purchase order for VMS+ components needed to support the manufacture of systems sufficient to support validation of the product and submission to CFDA. Lishman has committed to an investment into Ventripoint.

"We appreciate the ongoing commitment of our Chinese partners to VMS+," stated Hugh MacNaught, President and CEO. "Heart disease remains the number one healthcare issue in China with nearly twice the rate of hospital admissions for cardiovascular conditions than in North America. China has a higher rate of use of echocardiograms than in North America and is expected to benefit from both the performance improvements inherent to VMS+ that enable greater accuracy of echo studies and the ability of the system to work with sparse data that should reduce the number of repeat studies. Upon CFDA approval all 32,000 hospitals in China and its territories will gain awareness of a 2D echocardiography system that generates volumetric results with similar levels of accuracy to cMRI."

"We are looking forward to working closely with Ventripoint to integrate VMS+ within our platforms, secure CFDA approval, and actively market our solution to the Chinese clinical community" stated Paul Gibson, CTO of Lishman.

Pre-marketing efforts are underway in the Chinese market with the objective of establishing a presence within each of the 22 provinces plus the Special Administrative Regions within the country. There are over 2,500 Tier 1 hospitals and a total of 32,000 hospitals, with over 1,000 new hospitals currently under construction.

**About Lishman Global.**
Lishman Global was establish in 2012 to assist companies to safely enter the Chinese Market. Our partnership model allows foreign companies to navigate the complex network of regulatory approvals and multi-level distribution channels common in the Chinese medical device market.

**About Ventripoint Diagnostics Ltd.**

Ventripoint has become an industry leader in the application of AI (Artificial Intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary knowledge-based reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint's products that guide our future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe and Canada.

For further information, please contact:

Hugh MacNaught
hmacnaught@ventripoint.com
604-671-4201

**Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.**

**Forward Looking Statements**

This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "ongoing", "may", "will", "project", "should", "believe", "plans", "intends" and similar expressions are intended to identify forward-looking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Corporation. Although the Corporation believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Corporation can give no assurance that they will prove to be correct.

Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Factors which could materially affect such forward-looking information are described in

the risk factors in the Corporation's most recent annual management's discussion and analysis that is available on the Corporation's profile on SEDAR+ at www.sedarplus.ca. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Corporation undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.